This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
HealthdirectFree Australian health advice you can count on. — Description, Dosage, Side Effects | PillsCard
OTC
HealthdirectFree Australian health advice you can count on.
INN: BROLUCIZUMAB
Data updated: 2026-04-25
Available in:
🇨🇿🇬🇧🇫🇷🇵🇹🇷🇺🇸🇰
Form
—
Dosage
—
Route
—
Storage
—
About This Product
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Manufacturer
NOVARTIS PHARMACEUTICALS CANADA INC
ATC Code
S01LA06
Source
DPD · 02496984
USDailyMed:Brolucizumab
AU:D
S01LA06(WHO)
AU:S4(Prescription only)CA:℞-only/ Schedule DUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only)
1531589-13-5
252827371
8713
DB14864
none
XSZ53G39H5
D11083
Brolucizumabsold under trade nameBeovuamong others, is a humanized single-chain antibody fragment for the treatment ofneovascular (wet) age-related macular degeneration(AMD).
The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision).The most serious side effects are blindness,endophthalmitis(an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) andretinal detachment(separation of the retina from the back of the eye).
Brolucizumab was designed to attach to and block a substance calledvascular endothelial growth factorA (VEGF-A).VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
